Bristol-Myers Squibb Co. got a boost with promising data for its PD-1 inhibitor Opdivo in combination with drugs in a number of different classes, including the company's own assets – the CTLA-4 inhibitor Yervoy in first-line kidney cancer and its IDO inhibitor BMS 986205 in bladder cancer – plus Five Prime Therapeutics Inc.'s anti-CSF cabiralizumab in pancreatic cancer.
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.
